Skip to main content

Advertisement

SpringerLink
Log in

Genetic diversity and medicinal drug response in eye care

  • Review Article
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

Individual variation in drug response and adverse drug reactions are a serious problem in medicine. This inter-individual variation in drug response could be due to multiple factors such as disease determinants, environmental and genetic factors. Much has been published in the literature in recent years about the potential of pharmacogenetic testing and individualized medicine. The development of personalized medicine is truly an exciting area of research.

Methods

This pharmacogenetic concept in ophthalmology has existed for more than a century. Although substantial studies that link genetic variants to inter-individual difference in drug response have been reported in several diseases such as cancer and heart diseases, such studies are progressing slowly in the eye field. In this short article, an attempt has been made to summarize these results.

Results

Recently, there have been some small-scale studies that seem to associate the drug response to the genotype of patients in two major eye disorders, namely age-related macular degeneration (ARMD) and glaucoma.

Conclusion

These studies are still in their infancy, and do not suggest that a pharmacogenetic basis of drug development is a credible concept and can become reality in the future. This is because most drug responses involve a large number of genes that have several polymorphisms and it is unlikely that any one single gene dictates the drug response. Therefore, a polygenic approach, whole genome single nucleotide polymorphism (SNP) analysis and a molecular understanding of disease itself may provide a better insight in the future about genetic predisposing factors for adverse drug reactions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta analysis of prospective studies. JAMA 279:1200–1205

    Article  CAS  PubMed  Google Scholar 

  2. Dormann H, Neubert A, Criegee-Rieck M, Egger T, Radespiel-Troger M, Azaz-Livshits T, Levy M, Brune K, Hahan EG (2004) Readmissions and adverse drug reactions in internal medicine: the economic impact. J Int Med 255:653–663

    Article  CAS  Google Scholar 

  3. Shastry BS (2007) SNPs in disease gene mapping, medicinal drug development and evolution. J Hum Genet 52:871–880

    Article  CAS  PubMed  Google Scholar 

  4. Shastry BS (2006) Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J 6:16–21

    Article  CAS  PubMed  Google Scholar 

  5. Shastry BS (2005) Genetic diversity and new therapeutic concepts. J Hum Genet 50:321–328

    Article  CAS  PubMed  Google Scholar 

  6. Shastry BS (2004) Role of SNP/haplotype map in gene discovery and drug development: an overview. Drug Dev Res 62:142–150

    Article  Google Scholar 

  7. Shastry BS (2003) SNPs and haplotypes: genetic markers for disease and drug response. Int J Mol Med 11:379–382

    CAS  PubMed  Google Scholar 

  8. McLeod HL, Evans WE (2001) Pharmacogenomics: unlocking the human genome for better drug therapy. Ann Rev Pharmacol Toxicol 41:101–121

    Article  CAS  Google Scholar 

  9. Iida A, Saito S, Sekine A, Mishima C, Kitamura Y, Kondo K, Harigae S, Osawa S, Nakamura Y (2003) Catalog of 668 SNPs detected among 31 genes encoding potential drug targets on the cell surface. J Hum Genet 48:23–46

    Article  CAS  PubMed  Google Scholar 

  10. Moroi SE, Jr H (2008) Progress toward personalized medicine for age-related macular degeneration. Ophthalmology 115:925–926

    Article  PubMed  Google Scholar 

  11. Wiggs JL (2008) Genomic promise: personalized medicine for ophthalmology. Arch Ophthalmol 126:422–423

    Article  PubMed  Google Scholar 

  12. McCarty CA (2004) The promise and challenges of personalized medicine for eye diseases. Clin Exp Ophthalmol 32:236–237

    Article  Google Scholar 

  13. Schwartz SG, Mieler WF (2002) Medications and retinal toxicity. Ophthalmol Clin North Am 15:517–528

    Article  PubMed  Google Scholar 

  14. Baird PN, Hageman GS, Franzco RHG (2009) New era for personalized medicine: the diagnosis and management of age-related macular degeneration. Clin Exp Ophthalmol 37:814–821

    Article  Google Scholar 

  15. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK, SanGiovanni JP, Mane SM, Mayne ST, Bracken MB, Ferris FL, Ott J, Barnstable C, Hoh J (2005) Complement factor H polymorphism in age-related macular degeneration. Science 308:385–389

    Article  CAS  PubMed  Google Scholar 

  16. Edwards AO, Ritter RIII, Abel KJ, Manning A, Panhuysen C, Farrer LA (2005) Complement factor H polymorphism and age-related macular degeneration. Science 308:421–424

    Article  CAS  PubMed  Google Scholar 

  17. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, Spencer KL, Kwan SY, Noureddine M, Gilbert JR, Schnetz-Boutaud N, Agarwal A, Postel EA, Pericak-Vance MA (2005) Complement factor H variant increases the risk of age-related macular degeneration. Science 308:419–421

    Article  CAS  PubMed  Google Scholar 

  18. Zareparsi S, Branham KE, LI M, Shah S, Klein RJ, Ott J, Hoh J, Abecasis GR, Swaroop A (2005) Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration. Am J Hum Genet 77:149–153

    Article  CAS  PubMed  Google Scholar 

  19. Rivera A, Fisher SA, Fritsche LG, Keilhauer CN, Lichtner P, Meitinger T, Weber BH (2005) Hypothetical LOC 387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet 14:3227–3236

    Article  CAS  PubMed  Google Scholar 

  20. Dewan A, Liu M, Hartman S, Zhang SS, Liu DT, Zhao C, Tam PO, Chan WM, Lam DS, Snyder M, Barnstable C, Pang CP, Hoh J (2006) HTRA1 promoter polymorphism in wet age-related macular degeneration. Science 314:982–992

    Article  Google Scholar 

  21. Shastry BS (2006) Further support for the common variants in complement factor H (Y402H) and LOC 387715 (A69S) gene as major risk factors for the exudative age-related macular degeneration. Ophthalmologica 220:291–295

    Article  PubMed  Google Scholar 

  22. Shastry BS (2007) Assessment of the contribution of LOC 387715 gene polymorphism in a family with exudative age-related macular degeneration and heterozygous CFH variant (Y402H). J Hum Genet 52:384–387

    Article  PubMed  Google Scholar 

  23. Patel N, Adewovin T, Chong NV (2008) Age-related macular degeneration: a perspective on genetic studies. Eye 22:768–776

    Article  CAS  PubMed  Google Scholar 

  24. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two year results of the ANCHOR study. Ophthalmology 116:57–65

    Article  PubMed  Google Scholar 

  25. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR study group (2006) Ranibizumab verses verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444

    Article  CAS  PubMed  Google Scholar 

  26. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA study group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431

    Article  CAS  PubMed  Google Scholar 

  27. Steinbrook R (2006) The price of sight—ranibizumab, bevacizumab and the treatment of macular degeneration. N Engl J Med 355:1409–1412

    Article  CAS  PubMed  Google Scholar 

  28. Sheybani A, Kymes S, Schlief S, Apte R (2009) Vascular events in patients with age-related macular degeneration treated with intraocular bevacizumab. Retina 29:1404–1408

    Article  PubMed  Google Scholar 

  29. Brantley MA Jr, Fang AM, King JM, Tewari A, Kymes SM, Shiels A (2007) Association of complement factor H and LOC 387715 genotype with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 114:2168–2173

    Article  PubMed  Google Scholar 

  30. Lee AY, Rava AK, Kvmes SM, Shiels A, Brantley MA Jr (2009) Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 93:610–613

    Article  CAS  PubMed  Google Scholar 

  31. Lynch SS, Cheng CM (2007) Bevacizumab for neovascular ocular diseases. Ann Pharmacother 41:614–625

    Article  CAS  PubMed  Google Scholar 

  32. Parmeggiani F, Costagliola C, Gemmati D, D’Angelo S, Perri P, Scapoli GL, Catozzi L, Federici F, Sebastiani A, Incorvaia C (2007) Productive role of coagulation-balance gene polymorphisms in the efficacy of photodynamic therapy with verteporfin for classic choroidal neovascularization secondary to age-related macular degeneration. Pharmacogenet Genomics 17:1039–1046

    Article  CAS  PubMed  Google Scholar 

  33. Parmeggiani F, Gemmati D, Costagliola C, Sebastiani A, Incorvaia C (2009) Predictive role of C677T MTHFR polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration. Pharmacogenomics 10:81–95

    Article  CAS  PubMed  Google Scholar 

  34. Koenekoop RK, Lopez I, den Hollander AT, Allikmets R, Cremers FP (2007) Genetic testing for retinal dystrophies and dysfunctions: benefits, dilemmas and solutions. Clin Exp Ophthalmol 35:473–485

    Article  Google Scholar 

  35. Maeda M, Fujio Y, Azuma J (2006) MTHFR gene polymorphism and diabetic retinopathy. Curr Diabetes Rev 2:467–476

    CAS  PubMed  Google Scholar 

  36. Seitsonen SP, Jarvela IE, Meri S, Tommila PV, Ranta PH, Immonen IJ (2007) The effect of complement factor H Y402H polymorphism on the outcome of photodynamic therapy in age-related macular degeneration. Eur J Ophthalmol 17:943–949

    CAS  PubMed  Google Scholar 

  37. Feng X, Xiao J, Longville B, Tan AX, Wu XN, Cooper MN, McAllister IL, Isaacs T, Palmer LJ, Constable IJ (2009) Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration. Ophthalmology 116:1908–1912

    Article  PubMed  Google Scholar 

  38. Laine M, Seitsonen JH, Haapasalo K, Lehtinen MJ, Lindeman N, Anderson DH, Johnson PT, Jarvela I, Jokiranta TS, Hageman GS, Immonen I, Meri S (2007) Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol 178:3831–3836

    CAS  PubMed  Google Scholar 

  39. Immonen I, Seitsonen S, Tommila P, Kangas-Kontio T, Kakko S, Savolainen ER, Savolainen MJ, Liinamaa MJ (2010) Vascular endothelial growth factor gene variation and the response to photodynamic therapy in age-related macular degeneration. Ophthalmology 117:103–108

    Article  PubMed  Google Scholar 

  40. Klein ML, Francis PJ, Rosner B, Reynolds R, Hamon SC, Schultz DW, Ott J, Seddon JM (2008) CFH and LOC 387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. Ophthalmology 115:1019–1025

    Article  PubMed  Google Scholar 

  41. Weinberg RN, Khaw PT (2004) Primary open-angle glaucoma. Lancet 363:1711–1720

    Article  Google Scholar 

  42. Grant WM (1963) Glaucoma from topical corticosteroids. Arch Ophthalmol 70:445–446

    CAS  PubMed  Google Scholar 

  43. Becker B, Hahn KA (1964) Topical corticoids and heredity in primary open–angle glaucoma. Am J Ophthalmol 57:543–551

    CAS  PubMed  Google Scholar 

  44. Szabo V, Borgulya G, Filkorn T, Majnik J, Banyasz I, Nagy ZZ (2007) The variant N363S of glucocorticoid receptor in steroid-induced ocular hypertension in Hungarian patients treated with photorefractive keratectomy. Mol Vis 13:659–666

    CAS  PubMed  Google Scholar 

  45. Gerzenstein SM, Pletcher MT, Cervino AC, Tsinoremas NF, Young B, Puliafito CA, Fini ME, Schwartz SG (2008) Glucocorticoid receptor polymorphisms and intraocular pressure response to intravitreal triamcinolone acetonide. Ophthalmic Genet 29:166–170

    Article  CAS  PubMed  Google Scholar 

  46. Yang Y, Wu K, Yuan H, Yu M (2009) Cytochrome oxidase 2D6 gene polymorphism in primary open-angle glaucoma with various effects to ophthalmic timolol. J Ocul Pharmacol Ther 25:163–171

    Article  CAS  PubMed  Google Scholar 

  47. Nieminen T, Uusitalo H, Maenpaa J, Turjanmaa V, Rane A, Lundgren S, Ropo A, Rontu R, Lehtimaki T, Kahonen M (2005) Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. Eur J Clin Pharmacol 61:811–819

    Article  CAS  PubMed  Google Scholar 

  48. McCarty CA, Burmester JK, Mukesh BN, Patchett RB, Wilke RA (2008) Intraocular pressure response to topical beta blockers associated with an ADRB2 single-nucleotide polymorphism. Arch Ophthalmol 126:959–963

    Article  CAS  PubMed  Google Scholar 

  49. Fuchsjager-Mayrl G, Markovic O, Losert D, Lucus T, Wachek V, Muller M, Schmutterer L (2005) Polymorphism of the beta-2 adrenoceptor and IOP lowering potency of topical timolol in healthy subjects. Mol Vis 11:811–815

    CAS  PubMed  Google Scholar 

  50. Sakurai M, Higashide T, Takahashi M, Sugiyama K (2007) Association between genetic polymorphisms of the prostaglandin F2alpha receptor gene and response to latanoprost. Ophthalmology 114:1039–1045

    Article  PubMed  Google Scholar 

  51. MacDonald IM (2009) Pharmacogenetics—getting closer. Open Ophthalmol J 3:46–54

    Article  CAS  PubMed  Google Scholar 

  52. McLaren NC, Moroi SE (2003) Clinical implications of pharmacogenetics for glaucoma therapeutics. Pharmacogenomics J 3:197–201

    Article  CAS  PubMed  Google Scholar 

  53. Frueh FW, Gurwitz D (2004) From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. Pharmacogenomics 5:571–579

    Article  PubMed  Google Scholar 

  54. Richmond TD (2008) The current status and future potential of personalized diagnostics: streamlining a customized process. Biotechnol Ann Rev 14:411–422

    Article  Google Scholar 

Download references

Acknowledgement

My apologies to those whose work or original publications could not be cited in this short article because of limitations to the number of references.

Author information

Authors and Affiliations

  1. Department of Biological Sciences, Oakland University, Rochester, MI, USA

    Barkur S. Shastry

Authors
  1. Barkur S. Shastry
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Barkur S. Shastry.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shastry, B.S. Genetic diversity and medicinal drug response in eye care. Graefes Arch Clin Exp Ophthalmol 248, 1057–1061 (2010). https://doi.org/10.1007/s00417-010-1333-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-010-1333-x

Keywords

Search

Navigation